Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
c-Met Proto-Oncogene Receptor Tyrosine Kinase (c-Met)
- Target
- c-Met
- Molecular classification
- Receptor Tyrosine Kinase (RTK)
01
Overview
c-Met, also known as MET proto-oncogene, is a receptor tyrosine kinase (RTK) that serves as the high-affinity receptor for hepatocyte growth factor (HGF). Upon HGF binding, c-Met undergoes dimerization and autophosphorylation, activating downstream signaling pathways involved in cell proliferation, survival, motility, and invasion. Aberrant activation of c-Met, through mutation, amplification, or overexpression, is implicated in tumorigenesis across many cancers, making it a therapeutic target. Inhibitors targeting c-Met are under clinical investigation for various solid tumors.
- Other names
- MET proto-oncogeneHepatocyte Growth Factor Receptor (HGFR)Scatter Factor Receptor (SF Receptor)
02
Mechanism of action
Tyrosine kinase inhibition
03
Biological functions
Cell proliferationCell motilityCell survivalCell invasionWound healingAngiogenesisEmbryonic developmentOrganogenesis
04
Disease associations
Cancer (various solid tumors)Papillary renal cell carcinomaHepatocellular carcinomaNon-small cell lung cancer (NSCLC)Breast cancerOvarian cancerColon cancerKidney cancerThyroid cancer
05
Safety considerations
Resistance to inhibitorsOff-target effectsDevelopment of secondary malignancies
06
Interacting drugs
Crizotinib
07
Biomarkers
c-Met overexpressionMET gene amplificationMET mutations
Beyond the preview
Go deeper on c-Met Proto-Oncogene Receptor Tyrosine Kinase (c-Met).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on c-Met Proto-Oncogene Receptor Tyrosine Kinase (c-Met).